ADTX Aditxt, Inc.
Price Chart
Executive Summary
Aditxt's co-founder and CEO Amro Albanna resigned, along with director Shahrokh Shhabang and COO Rowena Albanna. The board appointed Jeffrey M. Busch, former CEO of a $1B NYSE-listed healthcare REIT, as Interim CEO and Brian Brady as non-executive Chairman. The press release outlines strategic priorities centered on commercializing the Ignite Proteomics precision oncology platform, but provides no financial data or guidance.
Actionable Insight
The complete C-suite departure of the co-founder CEO, COO, and a director at a micro-cap life sciences company with no revenue disclosed signals significant operational and strategic uncertainty. Monitor for the next 8-K amendment detailing Busch's compensation terms and any subsequent financing or business update filings. The stock's historical pattern shows extreme volatility on neutral filings (avg T+20 return -34.46% across 7 settled reports).
Key Facts
- CEO Amro Albanna resigned on May 29, 2026; director Shahrokh Shabahang resigned on May 31, 2026; COO Rowena Albanna resigned effective June 5, 2026.
- Jeffrey M. Busch appointed Interim CEO effective May 31, 2026; Brian Brady appointed non-executive Chairman.
- Busch previously founded and led Global Medical REIT (NYSE: GMRE) to over $1 billion in enterprise value, delivering ~8.5% average dividend yield.
- Interim CEO annual base salary of $500,000; final terms not yet finalized.
- No financial data, guidance, or preliminary results disclosed in the filing.
Financial Impact
No financial figures disclosed. Interim CEO base salary of $500,000 is the only compensation figure mentioned.
Risk Factors
- Complete departure of co-founder CEO and COO creates leadership vacuum and execution risk during a critical commercialization phase.
- No financial guidance or revenue figures provided; company's ability to continue as a going concern is a known risk per the forward-looking statements.
- Interim CEO's background is in healthcare REITs, not diagnostics or life sciences commercialization — sector mismatch risk.
- Historical performance on ADTX shows neutral filings have been followed by severe negative returns (avg -34.46% at T+20).
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063165 |
| Document: ea029290201ex99-1.htm | 0001213900-26-063165 |
| Document: 0001213900-26-063165-index-headers.html | 0001213900-26-063165 |
| Document: 0001213900-26-063165-index.html | 0001213900-26-063165 |
| Document: 0001213900-26-063165.txt | 0001213900-26-063165 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Insider Cluster
| $0.0136 awaiting T+5 | awaiting T+5 | — | $0.0130 (+4.41%) |
|
Jun 11, 2026
2d ago
|
Insider Cluster
| $0.0186 awaiting T+5 | awaiting T+5 | — | $0.0130 (+30.11%) |
|
Jun 10, 2026
2d ago
|
8-K
| $0.0186 awaiting T+5 | awaiting T+5 | — | $0.0130 (−30.11%) |
|
Jun 9, 2026
3d ago
|
8-K
| $0.0285 awaiting T+5 | awaiting T+5 | — | $0.0130 (+54.39%) |
|
Jun 8, 2026
4d ago
|
3
| $0.0497 awaiting T+5 | awaiting T+5 | — | $0.0130 (−73.84%) |
|
Jun 1, 2026
11d ago
|
8-K
| $0.1130 $0.0620 | ▼ −45.13% | ▼ −42.38% | $0.0130 (−88.50%) |
|
May 29, 2026
14d ago
|
8-K
| $0.1130 $0.0620 | ▲ +45.13% | ▲ +42.38% | $0.0130 (+88.50%) |
|
May 15, 2026
28d ago
|
8-K
| $1.63 $0.2550 | ▼ −84.31% | ▼ −85.93% | $0.0130 (−99.20%) |
|
May 8, 2026
5w ago
|
8-K
| $2.94 $1.63 | ▲ +44.78% | ▲ +44.70% | $0.0130 (+99.56%) |
|
Apr 23, 2026
7w ago
|
3
| $7.80 $5.27 | ▼ −32.53% | ▼ −34.00% | $0.0130 (−99.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access